-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Cancer patients have a higher risk of developing severe illness after being infected with the new crown pneumonia virus than ordinary people.
Infected with new coronary pneumonia
Researchers such as Shmueli conducted a prospective study on cancer patients vaccinated with the new crown vaccine BNT162b2 to monitor antibody response and safety to assess the seropositivity rate and determine predictors of non-reactive immune response
immunity
Patients with solid tumors receiving anti-cancer treatments and immunocompetent medical workers as controls were included
The RBD-binding IgG levels and neutralizing antibody titers of the two groups of subjects after the second dose of vaccine
The RBD-binding IgG levels and neutralizing antibody titers of the two groups of subjects after the second dose of vaccineA total of 129 patients were enrolled, of which 70.
The seroprevalence rates of cancer patients and the control group after the first vaccination were 32.
The occurrence of adverse reactions in cancer patients vaccinated with BNT162b2 vaccine
The occurrence of adverse reactions in cancer patients vaccinated with BNT162b2 vaccinePatients who were seronegative after the second dose of vaccine had significantly more complications than those who were seropositive (77.
Patients who were seronegative after the second dose of vaccine had significantly more complications than patients who were seropositive.
During anti-cancer treatment, cancer patients can obtain sufficient antibody response after receiving two injections of new crown vaccine BNT162b2 during anti-cancer treatment.
Original source:
Shmueli Einat S,Itay Amit,Margalit Ofer et al.
Efficacy and safety of BNT162b2 vaccination in patients with solid cancer receiving anticancer therapy - a single centre prospective study
in this message
